Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics, Strengthening Neuropsychiatric Portfolio
Supernus Pharmaceuticals, Inc. has completed its acquisition of Sage Therapeutics, enhancing its neuropsychiatric portfolio with the innovative product ZURZUVAE® and a new CNS discovery platform. This move is expected to boost Supernus’ revenue and cash flow growth, with anticipated annual cost synergies of up to $200 million, becoming accretive by 2026.
Supernus Pharmaceuticals, Inc. has announced the successful completion of its acquisition of Sage Therapeutics, Inc. This acquisition enhances Supernus’ presence in the field of neuropsychiatric conditions, bringing in an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform. The integration of Sage is expected to accelerate Supernus’ mid- to long-term revenue and cash flow growth while diversifying its revenue base. The company anticipates that the acquisition will result in annual cost synergies of up to $200 million and is expected to be accretive in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9503949-en) on July 31, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
